Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia (CLI) and other forms of peripheral arterial disease (PAD). CLI's severe blockage of arteries of the lower extremities markedly reduces blood flow, resulting in notable medical impacts and death...
More...
More...